CX Institutional’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.82M | Buy |
19,587
+2,307
| +13% | +$1.11M | 0.28% | 80 |
|
|
2026
Q1 | $8.49M | Buy |
17,280
+637
| +4% | +$346K | 0.26% | 87 |
|
|
2025
Q4 | $9.64M | Sell |
16,643
-173
| -1% | -$97.8K | 0.29% | 82 |
|
|
2025
Q3 | $8.16M | Buy |
16,816
+693
| +4% | +$323K | 0.25% | 96 |
|
|
2025
Q2 | $6.54M | Buy |
16,123
+5,967
| +59% | +$2.49M | 0.23% | 101 |
|
|
2025
Q1 | $5.05M | Buy |
10,156
+196
| +2% | +$106K | 0.19% | 122 |
|
|
2024
Q4 | $5.18M | Buy |
9,960
+2,062
| +26% | +$1.13M | 0.21% | 122 |
|
|
2024
Q3 | $4.89M | Buy |
7,898
+6,691
| +554% | +$3.96M | 0.22% | 127 |
|
|
2024
Q2 | $667K | Buy |
1,207
+13
| +1% | +$7.45K | 0.03% | 336 |
|
|
2024
Q1 | $694K | Buy |
1,194
+17
| +1% | +$9.54K | 0.03% | 327 |
|
|
2023
Q4 | $625K | Buy |
1,177
+222
| +23% | +$107K | 0.03% | 308 |
|
|
2023
Q3 | $483K | Sell |
955
-327
| -26% | -$174K | 0.03% | 330 |
|
|
2023
Q2 | $669K | Buy |
1,282
+85
| +7% | +$45.9K | 0.03% | 323 |
|
|
2023
Q1 | $685K | Buy |
1,197
+140
| +13% | +$78.9K | 0.04% | 323 |
|
|
2022
Q4 | $582K | Buy |
1,057
+441
| +72% | +$234K | 0.04% | 350 |
|
|
2022
Q3 | $312K | Buy |
616
+14
| +2% | +$7.83K | 0.02% | 387 |
|
|
2022
Q2 | $327K | Sell |
602
-25
| -4% | -$13.8K | 0.02% | 376 |
|
|
2022
Q1 | $370K | Buy |
627
+47
| +8% | +$27K | 0.03% | 290 |
|
|
2021
Q4 | $387K | Buy |
580
+31
| +6% | +$19.4K | 0.03% | 263 |
|
|
2021
Q3 | $314K | Buy |
549
+17
| +3% | +$9.33K | 0.03% | 312 |
|
|
2021
Q2 | $268K | Buy |
532
+15
| +3% | +$7.08K | 0.02% | 310 |
|
|
2021
Q1 | $236K | Buy |
517
+9
| +2% | +$4.3K | 0.02% | 288 |
|
|
2020
Q4 | $237K | Buy |
508
+26
| +5% | +$12.2K | 0.02% | 281 |
|
|
2020
Q3 | $213K | Buy |
482
+178
| +59% | +$73.5K | 0.02% | 258 |
|
|
2020
Q2 | $110K | Buy |
304
+22
| +8% | +$7.37K | 0.01% | 280 |
|
|
2020
Q1 | $80K | Buy |
282
+114
| +68% | +$35.9K | 0.01% | 287 |
|
|
2019
Q4 | $55K | Hold |
168
| – | – | 0.01% | 275 |
|
|
2019
Q3 | $49K | Buy |
168
+46
| +38% | +$13.2K | 0.01% | 299 |
|
|
2019
Q2 | $36K | Sell |
122
-9
| -7% | -$2.48K | 0.01% | 342 |
|
|
2019
Q1 | $36K | Buy |
+131
| New | +$32.6K | 0.01% | 348 |
|
Other funds holding TMO
CX Institutional's TMO Position: Q2 2026 in Review
CX Institutional increased its Thermo Fisher Scientific (TMO) stake by 13% in Q2 2026, buying an estimated $1.11M and bringing the position to 19,587 shares worth $9.82M. The position accounts for 0.28% of the portfolio, ranked #80.
CX Institutional first reported a position in TMO in Q1 2019 and has held it in 30 quarters since. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- CX Institutional held 19,587 shares of Thermo Fisher Scientific worth $9.82M as of Q2 2026.
- CX Institutional bought 2,307 Thermo Fisher Scientific shares in Q2 2026, an estimated $1.11M.
- Thermo Fisher Scientific made up 0.28% of CX Institutional's portfolio in Q2 2026, its #80 holding.
- CX Institutional first reported a position in Thermo Fisher Scientific in Q1 2019 and has held it in 30 quarters since.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.